ArteraAI Prostate
Prognostic AI test using digital pathology images for prostate cancer.
Answers a different question from a detection tool: not 'is there cancer' but 'how is this likely to behave'.
- Cost
- Paid
- Your data
- Not established
- Licence
- proprietary
- Maturity
- production
- From
- Artera, Inc.
What it is
Prognostic algorithm analysing digitised prostate biopsy images alongside clinical variables to inform risk assessment and therapy decisions. Created the SFH product code for prognostic pathology algorithms.
Caveats
Clearance is specific to the indication for use stated in the FDA record and to the United States. It implies nothing about availability or approval elsewhere. Verify the current indication and your own jurisdiction's status before clinical use.
Related
Catalogued 2026-08-02, last checked 2026-08-02. View the source record · Report an error